Spirogen seeks partner companies and institutions to work with it in a number of areas of drug and technology development. Spirogen is seeking collaboration opportunities in the following areas:
Complementary antibody and targeted prodrug activation technologies for Spirogen's novel, sequence-selective, cytotoxic agents
Potent cytotoxic agents based on small molecule DNA minor groove-binding, cross-linking and single strand-linking molecules are suited to both antibody-targeted and targeted prodrug therapies. Linking and protecting technologies have been developed and are available for testing with targeting systems. Spirogen is able to make material available for evaluation in the field of antibody drug conjugate therapy and for application with other targeting mechanisms.
If you are interested in potential partnering opportunities with Spirogen please contact Chris Martin. (chris.martin@spirogen.com) Tel : +44 (0)1983 817017 or +44 (0)7788 720572.